These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10091176)

  • 1. High incidence of osteoporosis in thalassaemia major.
    Jensen CE; Tuck SM; Agnew JE; Koneru S; Morris RW; Yardumian A; Prescott E; Hoffbrand AV; Wonke B
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():975-7. PubMed ID: 10091176
    [No Abstract]   [Full Text] [Related]  

  • 2. Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients.
    Gamberini MR; Fortini M; Gilli G; Testa MR; De Sanctis V
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():867-9. PubMed ID: 10091159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pattern of bone disease in transfusion-dependent thalassemia major patients.
    Katz K; Horev G; Goshen J; Tamary H
    Isr J Med Sci; 1994 Aug; 30(8):577-80. PubMed ID: 8045734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose tolerance and beta-cell secretion in patients with thalassaemia major.
    Mangiagli A; Italia S; Campisi S
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():985-6. PubMed ID: 10091179
    [No Abstract]   [Full Text] [Related]  

  • 5. Antioxidant micronutrients in children with thalassaemia in Egypt.
    Nasr MR; Ali S; Shaker M; Elgabry E
    East Mediterr Health J; 2002; 8(4-5):490-5. PubMed ID: 15603029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major.
    Wonke B; Jensen C; Hanslip JJ; Prescott E; Lalloz M; Layton M; Erten S; Tuck S; Agnew JE; Raja K; Davies K; Hoffbrand AV
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():795-801. PubMed ID: 10091149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac disease in beta-thalassaemia major: Is it reversible?
    Atiq M; Bana M; Ahmed US; Bano S; Yousuf M; Fadoo Z; Khurshid M
    Singapore Med J; 2006 Aug; 47(8):693-6. PubMed ID: 16865210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The mechanism of cataract formation in persons with beta-thalassemia].
    Popescu C; Siganos D; Zanakis E; Padakis A
    Oftalmologia; 1998; 45(4):10-3. PubMed ID: 10418622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary hypertension in thalassaemia major patients with normal left ventricular systolic function.
    Hagar RW; Morris CR; Vichinsky EP
    Br J Haematol; 2006 May; 133(4):433-5. PubMed ID: 16643452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of endocrine complications in beta-thalassaemia major in the Islamic Republic of Iran.
    Karamifar H; Shahriari M; Sadjadian N
    East Mediterr Health J; 2003; 9(1-2):55-60. PubMed ID: 15562733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone mineral density in children and young adults with beta-thalassemia major conventionally treated.
    Christoforidis A; Hatzipantelis E; Tsatra I; Kazantzidou E; Katzos G; Athanassiou-Metaxa M
    Pediatr Blood Cancer; 2006 Jul; 47(1):113-4; author reply 115. PubMed ID: 16602118
    [No Abstract]   [Full Text] [Related]  

  • 12. Low bone mineral density in adolescents with beta-thalassemia.
    Vogiatzi MG; Autio KA; Mait JE; Schneider R; Lesser M; Giardina PJ
    Ann N Y Acad Sci; 2005; 1054():462-6. PubMed ID: 16339698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An endocrinologist's commentary.
    Stanhope R
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():1001-2. PubMed ID: 10091185
    [No Abstract]   [Full Text] [Related]  

  • 14. Survival and complications in thalassemia.
    Borgna-Pignatti C; Cappellini MD; De Stefano P; Del Vecchio GC; Forni GL; Gamberini MR; Ghilardi R; Origa R; Piga A; Romeo MA; Zhao H; Cnaan A
    Ann N Y Acad Sci; 2005; 1054():40-7. PubMed ID: 16339650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine complications in patients with Thalassaemia Major.
    Toumba M; Sergis A; Kanaris C; Skordis N
    Pediatr Endocrinol Rev; 2007 Dec; 5(2):642-8. PubMed ID: 18084158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled trial of long-term chelation therapy in homozygous beta-thalassemia.
    Letsky EA
    Birth Defects Orig Artic Ser; 1976; 12(8):31-41. PubMed ID: 1009233
    [No Abstract]   [Full Text] [Related]  

  • 17. Tricuspid regurgitation in patients with beta-thalassemia major.
    Wu KH; Chang JS; Su BH; Peng CT
    Ann Hematol; 2004 Dec; 83(12):779-83. PubMed ID: 15449031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mineral density in Iranian adolescents and young adults with beta-thalassemia major.
    Shamshirsaz AA; Bekheirnia MR; Kamgar M; Pakbaz Z; Tabatabaie SM; Bouzari N; Pourzahedgilani N; Azarkeivan A; Hashemi SR; Moosavi F; Alebouyeh M; Vosough P; Kimiagar M; Shamshirsaz AA; Moradi M; Habibzadeh MR; Nobakhthaghighi N; Larijani B
    Pediatr Hematol Oncol; 2007; 24(7):469-79. PubMed ID: 17786783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of treatment with long-term chelating agents on iron overload in thalassaemia.
    Letsky EA; Flynn DM; Barry M
    Br J Haematol; 1973 Aug; 25(2):285. PubMed ID: 4726921
    [No Abstract]   [Full Text] [Related]  

  • 20. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.
    Pietrapertosa AC; Minenna G; Colella SM; Santeramo TM; Renni R; D'Amore M
    Panminerva Med; 2009 Mar; 51(1):17-23. PubMed ID: 19352306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.